Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $292.03 billion. The enterprise value is $303.54 billion.
| Market Cap | 292.03B |
| Enterprise Value | 303.54B |
Important Dates
The last earnings date was Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.61% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 19.91 and the forward PE ratio is 16.40.
| PE Ratio | 19.91 |
| Forward PE | 16.40 |
| PS Ratio | 6.65 |
| Forward PS | 1.11 |
| PB Ratio | 14.55 |
| P/TBV Ratio | 69.12 |
| P/FCF Ratio | 24.82 |
| P/OCF Ratio | 15.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.49, with an EV/FCF ratio of 25.80.
| EV / Earnings | 20.03 |
| EV / Sales | 6.91 |
| EV / EBITDA | 13.49 |
| EV / EBIT | 14.27 |
| EV / FCF | 25.80 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.86.
| Current Ratio | 0.74 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.46 |
| Interest Coverage | 41.95 |
Financial Efficiency
Return on equity (ROE) is 88.12% and return on invested capital (ROIC) is 47.91%.
| Return on Equity (ROE) | 88.12% |
| Return on Assets (ROA) | 23.29% |
| Return on Invested Capital (ROIC) | 47.91% |
| Return on Capital Employed (ROCE) | 58.02% |
| Revenue Per Employee | $567,845 |
| Profits Per Employee | $195,965 |
| Employee Count | 77,349 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.01 billion in taxes.
| Income Tax | 4.01B |
| Effective Tax Rate | 20.93% |
Stock Price Statistics
The stock price has decreased by -47.25% in the last 52 weeks. The beta is 0.21, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -47.25% |
| 50-Day Moving Average | 70.43 |
| 200-Day Moving Average | 99.63 |
| Relative Strength Index (RSI) | 52.43 |
| Average Volume (20 Days) | 11,788,373 |
Short Selling Information
The latest short interest is 25.12 million, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 25.12M |
| Short Previous Month | 14.66M |
| Short % of Shares Out | 0.79% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.44 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $43.92 billion and earned $15.16 billion in profits. Earnings per share was $3.40.
| Revenue | 43.92B |
| Gross Profit | 37.18B |
| Operating Income | 21.27B |
| Pretax Income | n/a |
| Net Income | 15.16B |
| EBITDA | 22.50B |
| EBIT | 21.27B |
| Earnings Per Share (EPS) | $3.40 |
Balance Sheet
The company has $6.02 billion in cash and $17.20 billion in debt, giving a net cash position of -$11.18 billion or -$2.52 per share.
| Cash & Cash Equivalents | 6.02B |
| Total Debt | 17.20B |
| Net Cash | -11.18B |
| Net Cash Per Share | -$2.52 |
| Equity (Book Value) | 20.07B |
| Book Value Per Share | 4.52 |
| Working Capital | -8.94B |
Cash Flow
In the last 12 months, operating cash flow was $19.02 billion and capital expenditures -$7.55 billion, giving a free cash flow of $11.77 billion.
| Operating Cash Flow | 19.02B |
| Capital Expenditures | -7.55B |
| Free Cash Flow | 11.77B |
| FCF Per Share | $2.65 |
Margins
Gross margin is 84.65%, with operating and profit margins of 48.43% and 34.51%.
| Gross Margin | 84.65% |
| Operating Margin | 48.43% |
| Pretax Margin | 43.65% |
| Profit Margin | 34.51% |
| EBITDA Margin | 51.23% |
| EBIT Margin | 48.43% |
| FCF Margin | 26.79% |
Dividends & Yields
This stock pays an annual dividend of $1.61, which amounts to a dividend yield of 2.38%.
| Dividend Per Share | $1.61 |
| Dividend Yield | 2.38% |
| Dividend Growth (YoY) | 17.49% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 47.38% |
| Buyback Yield | 0.61% |
| Shareholder Yield | 2.98% |
| Earnings Yield | 5.19% |
| FCF Yield | 4.03% |
Analyst Forecast
The average price target for Novo Nordisk is $128.00, which is 88.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $128.00 |
| Price Target Difference | 88.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 12.53% |
| EPS Growth Forecast (5Y) | 13.97% |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 7.88 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.88 |
| Piotroski F-Score | 5 |